Biopharmaceuticals use modern genetic engineering technology to recombine the DNA of microorganisms to produce drugs with high pharmacological activity, low side effects, and high nutritional value, including biomedicine and biomedicine. The biopharmaceutical industry is an industry that integrates biology, medicine, and pharmacy and is backed by basic disciplines such as molecular biology and molecular genetics. It has the characteristics of large investment, high returns, high risks, long cycles, and low pollution.
　　 1. Huge industrial development potential
　　Biopharmaceuticals have become the commanding heights of the pharmaceutical industry to compete for the market. Represented by monoclonal antibody drugs, including vaccines, blood products, recombinant protein drugs, peptide drugs, biological extracts, and gene therapy, a biopharmaceutical industry chain is taking shape.
　　 At present, my country’s self-developed biopharmaceutical products in 6 categories, 9 types and 21 specifications are on the market, and dozens of genetically engineered drugs are in different stages of preclinical or clinical research. 36 vaccine manufacturers have their own products. These vaccines cover all types of preventive vaccines, can be used to prevent and control infectious diseases, and can meet domestic needs in terms of quality and quantity. Among them, the hand-foot-mouth disease enterovirus 71 inactivated vaccine developed by Kexing Holdings has entered phase II clinical trials and is expected to become the world's first hand-foot-mouth disease inactivated vaccine.
　　 In terms of blood products, there are 33 GMP-certified blood product manufacturers in my country. These companies are represented by Beijing Kexing, Shanghai RAAS, Hualan Biology, and Tiantan Biology. In recent years, as the country continues to raise the threshold of blood products, my country's blood products industry will gradually move towards standardization, and will surely benefit from the benefits of industry integration in the future.
　　 In recent years, my country has developed a batch of new specific drugs that have significant effects on tumors and cardiovascular and cerebrovascular diseases. In addition, important recombinant proteins such as erythropoietin, insulin, interferon, and growth hormone have already been industrialized. All this fully reflects my country's achievements in the field of biopharmaceuticals, and even more shows that my country has the potential to develop the biopharmaceutical industry.
　　 2. Industrial base and innovation system construction
　　 Currently, my country has developed the biopharmaceutical industry as a key construction industry and a high-tech pillar industry. Establish a national biopharmaceutical industry base in economically developed or technologically developed areas. Shanghai Pudong has gathered more than 430 biopharmaceutical industry companies, forming a biopharmaceutical industry cluster that has begun to take shape, which can well promote the development of the entire biopharmaceutical industry. Among them, Zhangjiang High-tech Park, also known as Zhangjiang "Medicine Valley", has introduced a total of 328 biopharmaceutical companies and has more than 9,000 full-time scientific researchers. It has initially formed a group of industries, research and development, incubation innovation, education and training, and professional services. , Modern biomedicine innovation system composed of venture capital modules.
　　 3. R&D outsourcing quickly R&D outsourcing
　　 The shift from developed countries to emerging markets has brought unlimited business opportunities to China, which is in the process of industrialization. Currently, labor costs have accounted for more than 50% of the international pharmaceutical research and development costs. my country not only has high-quality and low-cost human resources, but also has a huge consumer market, which provides strong support for attracting multinational pharmaceutical companies to establish R&D centers in my country. At present, the market size of my country's pharmaceutical R&D outsourcing has reached RMB 4 billion, and is growing rapidly at an average annual rate of 100%.
　　Beijing, Shanghai, Tianjin and many other cities have included pharmaceutical R&D outsourcing services as an important part of the local development of the productive service industry, and identified them as new economic growth points.
　　 At present, there are 20,000 people engaged in biopharmaceutical research in my country, and about 5,000 college students and graduate students graduate every year. An already competitive research team has begun to take shape.
　　 4. Facing market expansion
　　 Biopharmaceutical companies continue to emerge. As early as 2000, there were more than 200 biotechnology companies in my country, including leading companies such as Tianjin TEDA and Shenzhen Kexin. In addition, with the development of my country's economy, people's ability to pay has improved, and the biopharmaceutical market has continued to grow. While the market scale of my country's biopharmaceutical industry has maintained rapid growth, technological achievements have been further accelerated.
　　The increase in national investment has stimulated people's demand for vaccines, and has also provided a good opportunity for the development of unplanned immunization vaccines. This shows that the biopharmaceutical industry has a good development prospect in my country.